Published Research and Presentations

SUB-urothelial Durvalumab InjEction – 1 (SUBDUE-1) – Results from the first nine urothelial cancer patients using a dose-escalation schedule

Other

ASCO GU 2022

19/02/2022

Dickon Hayne, Nicole Swarbrick, Stephen McCombie, Andrew Moe, Cynthia Hawks, Pravin Viswambaram, Ciara Conduit, Elizabeth Chien Hern Liow, Lisa Spalding, Jarrad Bothe, Tom Ferguson, Andrew James Martin, Ian D. Davis, Andrew David Redfern, on behalf of The Australian and New Zealand Urogenital and Prostate Cancer Trials Group

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate –a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801)

DASL-HiCaP

ASCO GU 2022

19/02/2022

S M McBride, T Niazi, S Williams, I D Davis, M R Stockler, A J Martin, K Bracken, F T Roncolato, L Horvath, S Sengupta, J Martin, T S Lim, S Hughes, R McDermott, J Catto, P Kelly, W Parulekar, S C Morgan, R Rendon and C J Sweeney, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

ENZA-p

ASCO GU 2022

19/02/2022

Louise Emmett, Shalini Subramaniam, Andrew James Martin, Alison Yan Zhang, Sonia Yip, Megan Crumbaker, Nisha Rana, Roslyn J. Francis, Michael S. Hofman, Anthony M. Joshua, Shahneen Kaur Sandhu, Arun Azad, Craig Gedye, Andrew James Weickhardt, Jeffrey C. Goh, Siobhan Ng, Mark Voskoboynik, Margaret M McJannett, Martin R. Stockler, Ian D. Davis, on behalf of the the Australian and New Zealand Urogenital and Prostate Cancer Trial